AstraZeneca receives CDSCO approval to launch eculizumab in India

Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome

AstraZeneca appoints Iskra Reic as Executive Vice President, International

Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca

AstraZeneca Pharma Pharma India to launch Breztri Aerosphere in Jan 2025

AstraZeneca invests US$ 3.5 billion in R&D and manufacturing in US

This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs

AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr

We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%

AstraZeneca China President currently under investigation

Our China operations continue under the leadership of the current General Manager of AstraZeneca China

AstraZeneca advances science of infectious disease protection at IDWeek 2024

Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19

AstraZeneca, CSPC Pharmaceutical agree for a pre-clinical novel lipid-lowering therapy

CSPC will receive an upfront payment of $100 million from AstraZeneca

AstraZeneca Pharma India to launch Tremelimumab

Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma

AstraZeneca Pharma India to launch Palivizumab (Synagis) in October 2024

Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease